Neurocrine Biosciences, Inc. $NBIX Holdings Decreased by Curated Wealth Partners LLC

Curated Wealth Partners LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 93.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,021 shares of the company’s stock after selling 44,694 shares during the quarter. Curated Wealth Partners LLC’s holdings in Neurocrine Biosciences were worth $428,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. NewEdge Advisors LLC raised its stake in shares of Neurocrine Biosciences by 0.5% during the first quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock valued at $1,721,000 after acquiring an additional 68 shares during the last quarter. Westpac Banking Corp lifted its holdings in shares of Neurocrine Biosciences by 6.0% during the first quarter. Westpac Banking Corp now owns 1,615 shares of the company’s stock worth $213,000 after purchasing an additional 91 shares during the period. PKO Investment Management Joint Stock Co grew its stake in shares of Neurocrine Biosciences by 7.7% in the first quarter. PKO Investment Management Joint Stock Co now owns 1,400 shares of the company’s stock worth $184,000 after purchasing an additional 100 shares during the last quarter. Meiji Yasuda Life Insurance Co increased its holdings in Neurocrine Biosciences by 1.8% in the second quarter. Meiji Yasuda Life Insurance Co now owns 5,628 shares of the company’s stock valued at $949,000 after purchasing an additional 100 shares during the period. Finally, SJS Investment Consulting Inc. increased its holdings in Neurocrine Biosciences by 67.2% in the first quarter. SJS Investment Consulting Inc. now owns 341 shares of the company’s stock valued at $45,000 after purchasing an additional 137 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NBIX shares. Wall Street Zen lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. Wells Fargo & Company upped their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Mizuho upgraded Neurocrine Biosciences to a “hold” rating in a research report on Wednesday, September 16th. TD Cowen increased their price target on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Zacks Research downgraded Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.14.

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,311 shares of the company’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the sale, the chief financial officer owned 42,808 shares in the company, valued at $6,729,417.60. This represents a 5.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David W. Boyer sold 826 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.45, for a total value of $130,053.70. Following the sale, the insider directly owned 8,722 shares of the company’s stock, valued at $1,373,278.90. This represents a 8.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 4,387 shares of company stock valued at $720,855. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Down 0.9%

NBIX opened at $135.71 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $186.12. The company has a fifty day moving average of $149.10 and a 200-day moving average of $153.45. The stock has a market cap of $13.79 billion, a PE ratio of 18.92, a price-to-earnings-growth ratio of 0.60 and a beta of 0.40.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. The business had revenue of $959.00 million during the quarter, compared to the consensus estimate of $891.16 million. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. Neurocrine Biosciences’s quarterly revenue was up 39.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.65 earnings per share. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 7.70 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and related disorders. The company is headquartered in San Diego, California, and conducts research through internal programs and collaborations with academic institutions and other pharmaceutical companies.

Neurocrine’s principal commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington’s disease.